“OSSIFY Reaches the Final in TÜBİTAK BIGG-1832 Support Program, Pioneering a Breakthrough in Osteoporosis Management”
One of Turkey’s leading technology development initiatives, the OSSIFY software, has reached the finals of the TÜBİTAK BIGG-1832 support program, marking a significant achievement in the use of artificial intelligence and genetic testing for osteoporosis diagnosis and treatment.
As osteoporosis becomes a serious public health issue among the aging global population, the goal of the OSSIFY project is to provide an innovative solution to this problem. The OSSIFY software analyzes patients’ genetic makeup to predict osteoporosis development risks and offers personalized treatment plans.
This technology increases the rates of early diagnosis, ensuring accurate detection and helping to prevent osteoporotic fractures.
Additionally, the use of artificial intelligence and genetic testing in the project plays a crucial role in assessing responses to osteoporosis treatments and reducing costs in health systems. Developed using advanced neural network libraries like Keras and the Python programming language, OSSIFY offers a user-friendly, scalable, and flexible solution. As a superior alternative to traditional bone density tests, it enables more accurate and earlier detection of disease risk.
This project is designed to improve the quality of healthcare services while playing a more effective role in the early diagnosis of osteoporosis. OSSIFY’s success is a promising example of how genetic and AI-based approaches can revolutionize modern medicine. All eyes are now on whether this innovative approach will be selected among other finalists by TÜBİTAK and if it will be implemented on a large scale.